SCHEMBL6467503

SCHEMBL6467503

CC(C)(C)[Si](C)(C)OC(c1nc2ccccc2o1)[C@H](CCc1ccccc1)NC(=O)N(CCC1CCCCC1)C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.33
PPARG P37231 2/20 0.31
PPARA Q07869 1/20 0.31
PRSS8 Q16651 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6462857 0.89 REN (0.32) RENPPARGPPARA
SCHEMBL6464251 0.78 REN (0.41) REN
SCHEMBL6466278 0.75 BMP1 (0.36) RENPPARGPPARA
SCHEMBL7183373 0.72 CTSS (0.55)
SCHEMBL6463634 0.71 FPR2 (0.47) REN
SCHEMBL7049337 0.71 PRSS8 (0.45) RENPRSS8
SCHEMBL6467029 0.69 LMNA (0.38)
SCHEMBL7048358 0.69 SMN1; SMN2 (0.38) PRSS8
SCHEMBL7049041 0.67 ATM (0.38) PPARGPPARAPRSS8
SCHEMBL6463649 0.66 MEN1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP disclosed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US disclosed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ REN 201/4885PPARG 4143/4885PPARA 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.